Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol

DNA Repair

Volumn 11, Issue 5, 2012, Pages 522-524

  Alli, Elizabeth ^a   Ford, James M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Basal like breast cancer; Base excision repair; Breast cancer; Cancer therapy; Elesclomol; Oxidative DNA damage

Indexed keywords

BRCA1 PROTEIN; DNA; DNA BASE; ELESCLOMOL;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; EXCISION REPAIR; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; FEMALE; GENES, BRCA1; HUMANS; HYDRAZINES; MICE; MUTATION; REACTIVE OXYGEN SPECIES; RECEPTOR, ERBB-2;

EID: 84860227954     PISSN: 15687864     EISSN: 15687856     Source Type: Journal    
DOI: 10.1016/j.dnarep.2012.02.003     Document Type: Article

References (14)

1. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
2. Hu Z., Fan C., Oh D.S., Marron J.S., He X., Qaqish B.F., Livasy C., Carey L.A., Reynolds E., Dressler L., Nobel A., Parker J., Ewend M.G., Sawyer L.R., Wu J., Liu Y., Nanda R., Tretiakova M., Ruiz Orrico A., Dreher D., Palazzo J.P., Perreard L., Nelson E., Mone M., Hansen H., Mullins M., Quackenbush J.F., Ellis M.J., Olopade O.I., Bernard P.S., Perou C.M. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
3. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., Hernandez-Boussard T., Livasy C., Cowan D., Dressler L., Akslen L.A., Ragaz J., Gown A.M., Gilks C.B., van de Rijn M., Perou C.M. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004, 10:5367-5374.
4. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lonning P., Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10869-10874.
5. Alli E., Sharma V.B., Sunderesakumar P., Ford J.M. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res. 2009, 69:3589-3596.
6. Kirshner J.R., He S., Balasubramanyam V., Kepros J., Yang C.Y., Zhang M., Du Z., Barsoum J., Bertin J. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol. Cancer Ther. 2008, 7:2319-2327.
7. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
8. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., Santarosa M., Dillon K.J., Hickson I., Knights C., Martin N.M., Jackson S.P., Smith G.C., Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
9. Hastak K., Alli E., Ford J.M. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010, 70:7970-7980.
10. Foulkes W.D. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam. Cancer 2006, 5:135-142.
11. Kennedy R.D., Quinn J.E., Mullan P.B., Johnston P.G., Harkin D.P. The role of BRCA1 in the cellular response to chemotherapy. J. Natl. Cancer Inst. 2004, 96:1659-1668.
12. Sgagias M.K., Wagner K.U., Hamik B., Stoeger S., Spieker R., Huber L.J., Chodosh L.A., Cowan K.H. Brca1-deficient murine mammary epithelial cells have increased sensitivity to CDDP and MMS. Cell Cycle 2004, 3:1451-1456.
13. Alli E., Sharma V.B., Hartman A.R., Lin P.S., McPherson L., Ford J.M. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol. 2011, 11:7.
14. O'Day S., Gonzalez R., Lawson D., Weber R., Hutchins L., Anderson C., Haddad J., Kong S., Williams A., Jacobson E. Phase II randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2009, 27:5452-5458.